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Early detection of symmetrical distalsensorimotor polyneuropathy (PNP) isimportant in patients with diabetes
because preventive interventions can be
applied to decrease morbidity (1). Unfortu-
nately, no “gold standard” exists for diag-
nosing PNP, but a consensus panel has
recommended that at least 1 measurement
should be performed in 5 different diag-
nostic categories. One of these categories is
a standardized physical examination (2,3).
In our opinion, diagnostic tests should ful-
fill the following criteria: validation (pres-
ence of an independent reference standard,
adequate spectrum and number of patients,
standardization, soundly based item selec-
tion), predictive value, manageability
(reproducibility, performance in clinical 
practice), and hierarchy. Frequently used
and accepted examination scores for dia-
betic neuropathy are the Neuropathy Dis-
ability Score (NDS) (4), the Neuropathy
Impairment Score in the Lower Limbs (NIS-
LL) (5,6), various modified NDS scores
(7,8), the Neuropathy Deficit Score (9), the
Michigan Neuropathy Screening Instru-
ment (MNSI) (10), and the Clinical Exami-
nation Score of Valk (CE-V) (11).
The NDS was designed for neuropathy
in general (4). Although the score is well
founded and complete, it is difficult to per-
form in clinical practice on patients with dia-
betic foot problems. Precise descriptions of
how the tests should be performed and how
items should be scored are lacking. The NIS-
LL is a modification of the NDS specific for
distal PNP, although motor activity grading is
the focus and involves 64 of a maximum of
88 points (5,6). The NIS-LL has not been
validated. Various other modified NDS scor-
ing systems have been used, such as those of
Veves et al. (7) and Young et al. (8); however,
these instruments also have not been vali-
dated, and no information is available on
their predictive value regarding the results of
clinical standards. The Neuropathy Deficit
Score is a neurological examination score
aimed at anatomical levels in the legs and
arms (9). It has not been validated, and no
information is available about how to inter-
pret modifications, which is also the case for
the other modified NDS scoring systems
(7,8). Feldman et al. (10) developed a com-
bination of 2 scoring systems: the MNSI
(symptom and examination score) and the
Michigan Diabetic Neuropathy Score (neu-
rological examination and nerve conduc-
tion studies). These scores do not have a
separate examination score as advised by
consensus reports (2,3). The CE-V can be
used to examine sensory functions, tendon
reflexes, and muscle strength in the lower
extremities (11). The scoring systems of
Feldman et al. (10) and Valk et al. (11) have
been validated and are easy to perform in
clinical practice. None of the aforemen-
tioned scores is known to be hierarchical.
The aim of this study was to adapt the
NDS into a valid, easily managed, graded,
and accurate scoring system for diagnosing
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Diabetic Neuropathy Examination
A hierarchical scoring system to diagnose distal polyneuropathy in
diabetes
OBJECTIVE — Existing physical examination scoring systems for distal diabetic polyneu-
ropathy (PNP) do not fulfill all of the following criteria: validity, manageability, predictive value,
and hierarchy. The aim of this study was to adapt the Neuropathy Disability Score (NDS) to
diagnose PNP in diabetes so that it fulfills these criteria.
RESEARCH DESIGN AND METHODS — A total of 73 patients with diabetes were
examined with the NDS. Monofilaments and biothesiometry were used as clinical standards for
PNP to modify the NDS.
RESULTS — A total of 43 men and 30 women were studied; mean duration of diabetes was
15 years (1–43), and mean age was 57 years (19–90). A total of 24 patients had type 1 diabetes,
and 49 patients had type 2 diabetes. Clinically relevant items were selected from the original
35 NDS items (specific item scored positive in .3 patients). The resulting 8-item Diabetic Neu-
ropathy Examination (DNE) score could accurately predict the results of the clinical standards
and is strongly hierarchical (H value 0.53). The sensitivity and specificity of the DNE at a cut-
off level of 3 to 4 were 0.96 and 0.51 for abnormal monofilament scores, respectively. For
abnormal vibration perception threshold scores, these values were 0.97 and 0.59, respectively.
Reproducibility as assessed by inter- and intrarater agreement was good.
CONCLUSIONS — The DNE is a sensitive and well-validated hierarchical scoring system
that is fast and easy to perform in clinical practice.
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PNP, the Diabetic Neuropathy Examina-
tion (DNE) score.
RESEARCH DESIGN AND 
METHODS
Patients
Our study group consisted of 73 patients
with diabetes. Exclusion criteria were fac-
tors that may interfere with the neurological
condition of the subjects other than PNP. A
total of 50 patients were randomly selected
from the diabetes outpatient clinic of Uni-
versity Hospital (Groningen, the Nether-
lands). A total of 23 patients with obvious
diabetic foot complications or clinical neu-
ropathy were selected from the Department
of Diabetes at the Rehabilitation Centre
Beatrixoord. The characteristics of these 73
patients are shown in Table 1.
Methods
The same researcher ( J.-W.G.M.) examined
all 73 patients. First, the NDS and NIS-LL
were performed followed by quantitative
sensory tests that acted as a clinical standard.
NDS and NIS-LL
The NDS is the most widely used and
widely accepted scoring system for diabetic
neuropathy; it has also been recommended
in consensus reports (2–4). The instrument
examines cranial nerves, muscle weakness,
reflexes, and sensation (4). The scale con-
sists of 35 items for testing the left and right
sides of the body; scores range from 0 to 4.
A sum score is obtained with a maximum
of 280 points.
The NIS-LL is a modified version of the
NDS to quantify diabetic PNP. The lower-
limb items of the NDS are used comple-
mented with 2 muscle power items (toe
extension and toe flexion). The NIS-LL has
14 items: 8 items evaluate muscle power
(0–4 points), 2 items evaluate reflexes (0–2
points), and 4 items evaluate sensory modal-
ities (0–2 points). All items are tested on
both sides. The maximum score is 88 points.
The NDS, as the most complete and
accepted score, was used for item selection
to develop the DNE.
Clinical standards
Semmes-Weinstein monofilaments and bio-
thesiometry were chosen as clinical stan-
dards to study the construct validity of the
scoring system for PNP. Semmes-Weinstein
monofilaments were tested on the plantar
surface of the hallux and centrally at the
heel (when necessary after removal of exces-
sive calluses). This method was standard-
ized according to generally accepted
guidelines (12–15). The “yes/no” method
was used, which means that the patient
says “yes” each time he or she senses the
application of a monofilament. Six trials
were administered; when the patient was
unable to respond correctly in more than 1
trial, a heavier monofilament was used. The
1-, 10-, and 75-g monofilaments were used.
We present the results in 4 categories: cate-
gory 1, 1-g monofilament felt; category 2,
10-g monofilament felt and 1-g monofila-
ment not felt; category 3, 75-g monofila-
ment felt and 10-g monofilament not felt;
and category 4, 75-g monofilament not felt.
Vibration perception thresholds (VPTs)
were determined using a hand-held bio-
thesiometer (Biomedical Instruments,
Newbury, OH). VPT was tested at the dor-
sum of the hallux on the interphalangeal
joint. It was performed in a standardized
way (15,16). The voltage of vibration was
increased until the patient could perceive a
vibration. This was done 3 times. The
mean of these 3 trials was used to deter-
mine the VPT.
Reproducibility
To test reproducibility, inter- and intrarater
agreement were assessed in a separate
study of 10 patients. The 6 women and 4
men with a mean ± SD age of 50.0 ± 15.9
years had a wide range of neuropathy
severity. The mean duration of diabetes was
11.5 ± 10.5 years; 3 participants had type 1
diabetes, and 7 participants had type 2 dia-
betes. Two experienced physicians, an
endocrinologist (E.E.B.) and a physiatrist
( J.-W.G.M.), both experienced in diagnos-
ing diabetic neuropathies, rated these
patients twice within 1 week.
Statistical analyses
The internal consistency of the DNE was
assessed by calculating Cronbach’s a and
reliability coefficient r (17), which are com-
parable with a. In addition to internal con-
sistency, scalability coefficient H was
computed with the probabilistic scaling
program of Mokken Scaling Polychoto-
mous (MSP) items to assess the hierarchical
structure of the items (17). High values of
coefficient H increase the likelihood that
patients with the same scale score have dif-
ficulties or problems with the same items.
The statistical package SPSS-PC (Chi-
cago) was used to compute the descriptive
statistics, factor analysis, reliability coeffi-
cient Cronbach’s a, Pearson’s correlation
coefficient r, and Student’s t test.
Inter- and intrarater agreement were
assessed on a scale level by computing
Pearson’s correlation coefficients and t test
values for differences in means.
RESULTS — Items were excluded from
the original NDS if they conformed to the
following definition of clinical irrelevance:
specific item scored positive in .3
patients. After examining the patients, 9 of
the original 35 items remained. No rele-
vant differences were found between the
measurements made on the left and right
sides, so only the right-side items were used
in the analyses.
Factor analysis was performed on the 9
items to investigate coherence. The coher-
ence of the 8 items was good; only item 22
(muscle strength in triceps surae) had poor
coherence compared with the other items.
Calculation of hierarchy was per-
formed using the MSP items. This resulted
in a hierarchical scale of 8 items. Item 22
disturbed the hierarchy severely. Logistical
regression analysis was performed to study
whether item 22, in addition to the 8-item
hierarchical scale, could predict the results
of the clinical standards VPT and monofil-
aments. Item 22 did not make any signifi-
cant contribution, so it was excluded.
Modification of the NDS resulted in an
8-item scale, the DNE. The DNE is shown
in the Appendix. The reliability of the scale
was assessed by measuring the internal
consistency. According to both Cronbach’s
Table 1—Patient characteristics
n 73
Mean age (years) 56.9 ± 16.1 (19–90)
Mean duration of diabetes (years) 14.9 ± 9.9 (1–43)
Sex (M/F) 43/30
Type of diabetes (type 1/type 2) 24/49
Mean HbA1c (%) 8.7 ± 1.4 (6.6–13.5)
Data are n or means ± SD (ranges).
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a (0.78) and reliability coefficient r (0.81),
the scale appears to be reliable. The H value
for hierarchy was 0.53, which indicates the
presence of a strong hierarchical scale (17).
Table 2 shows characteristics of the
DNE, NDS, and NIS-LL. As expected, the
correlation between the DNE and the NDS
(Pearson’s r = 0.96, P , 0.001) and NIS-LL
(Pearson’s r = 0.92, P , 0.001) were both
high. The reliability of the scoring systems
was good.
The DNE is fast and easy to perform in
clinical practice; application takes ,5 min.
Relationship of the NDS, NIS-LL, and
DNE with the clinical standards
Pearson’s correlation coefficient r for
monofilaments with the NDS, NIS-LL, and
DNE was similar with values of 0.76 (P ,
0.001), 0.74 (P , 0.001), and 0.75 (P ,
0.001), respectively. Pearson’s correlation
coefficient r for VPT with the NDS, NIS-LL,
and DNE was similar with values of 0.73
(P , 0.001), 0.71 (P , 0.001), and 0.75
(P , 0.001), respectively. The NDS, NIS-LL,
and DNE predicted the results of the clinical
standards very accurately (P , 0.001).
At a cutoff point of 3 to 4, the sensitiv-
ity and specificity of the DNE were 0.96
and 0.51, respectively, for an abnormal
result using monofilaments. For an abnor-
mal result using the VPT, these values were
0.97 and 0.59, respectively.
Reproducibility
Reproducibility of the DNE was assessed by
comparing the scores of 2 raters obtained
on 2 occasions (interval of 1 week). The
interrater correlation was 0.97 at t1 and
0.92 at t2. Differences in mean scores were
,10% and were not significant (P = 0.08
and P = 0.55, respectively). The intrarater
correlation was 0.89 for 1 rater and 0.99 for
the other. The mean scores of the 2 raters
did not differ significantly at t1 and t2 (P =
0.17 and P = 0.60, respectively).
CONCLUSIONS — The NDS is a
widely accepted and validated physical
examination scoring system used to diag-
nose neuropathy. Its predictive value and
reproducibility are high. It is well correlated
with neurophysiological and sural nerve
morphometric abnormalities in patients
with diabetes (4,18–21). Because the aim of
the NDS is to evaluate neuropathy in gen-
eral, it is not completely suitable for use at
an outpatient diabetic foot clinic. Conse-
quently, several other scoring systems have
been developed, but they do not sufficiently
fulfill all of the criteria necessary for ade-
quate diagnostic tests. One of these tests is
the NIS-LL (a score for distal diabetic PNP),
which has 14 items. The score has not been
validated and focuses more on motor prob-
lems than on sensory problems (5,6).
In this study, the NDS was modified
once again with the aim of achieving a new
physical examination scoring system for
diagnosing distal symmetrical PNP in dia-
betes. The new instrument is the DNE,
which is a scoring system with 8 items. It
was validated in diabetic patients with a
wide spectrum of complications. The DNE
is hierarchical, sensitive, fast, and easy to
perform in clinical practice (application took
,5 min). Hierarchy implies that patients
with the same scale score have difficulties or
problems with the same items, which makes
this scoring system able to differentiate
between severity levels of PNP and to com-
pare groups or individuals over time. The
NDS, NIS-LL, and the other instruments for
evaluating PNP have not been documented
to represent a hierarchical scale.
Our modifications were validated with
monofilament measurements and VPTs.
These are both semiquantitative reliable
measurements with proven predictive
value for the development of clinical prob-
lems such as foot ulcers and amputations.
They are noninvasive, patient friendly,
independent, and complementary (12–16).
Monofilaments and VPTs only assess large
fiber function; no small fiber tests have
been used in this study. Testing the DNE on
a random sample from the outpatient clinic
in addition to a set of patients with definite
neuropathy means that the results are gen-
eralizable to the complete range of patients
with diabetes.
Many clinicians prefer using electro-
diagnostic techniques to diagnose diabetic
PNP. Although neurophysiological exami-
nation is sensitive, specific, and repro-
ducible regarding the presence and severity
of peripheral nerve involvement in
patients with diabetes (18), it is not suit-
able for making a quick preliminary diag-
nosis at a diabetes outpatient clinic. No
data are available on the predictive value
of these techniques in relation to the
development of clinical problems such as
diabetic foot disease.
Because the aim of this study was to
develop a screening instrument as a tool in
the detection and prevention of patients at
risk for diabetic foot complications, the
observed sensitivity and specificity of the
DNE are satisfactory. Because sensitivity is
of greater importance than specificity for
screening instruments, the chosen cutoff
value results in the desired high sensitivity
with an acceptable specificity. A low speci-
ficity might burden prevention education
programs. The combined use of different
diagnostic tools, as advised in consensus
reports, will enhance specificity.
The selection of the muscle strength of
the quadriceps femoris item in the DNE is
surprising and suggests the presence of
mononeuropathy. Nevertheless, all patients
with quadriceps dysfunction also showed
other abnormalities regarding sensations in
the feet that were not related to the same
peripheral nerves, which makes mononeu-
ropathy less probable. The ankle dorsiflex-
ion item was excluded because of poor
coherence and disturbance of hierarchy. It
did not contribute to the 8 definite items.
Perhaps this discrepancy in muscle
strength and its assessment is because of
other factors such as limited joint mobility.
The results of validation and the pre-
dictive value of the NDS, NIS-LL, and
DNE were very satisfactory. The strengths
of the DNE are its manageability in clinical
practice and its hierarchy. The DNE is the
most efficient according to the criteria
shown in Table 2.
Table 2—Characteristics of the NDS, NIS-LL, and DNE in our study population (n = 73)
NDS NIS-LL DNE
Mean score 19.7 ± 14.5 9.7 ± 7.9 5.0 ± 3.6
Reliability (a) 0.88 0.87 0.78
Items 70 28 8
Maximum score 280 88 16
Maximum scored 56 32 13
Items not scored 44 1 0
,3 scores 8 3 0
Data are n or means ± SD, unless otherwise indicated.
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In conclusion, the DNE as modified
from the NDS is fast, easy to perform, hier-
archical, and sensitive for PNP, and patient
scores are more differentiated.
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1. Quadriceps femoris: extension of the
knee




4. Sensitivity to pinpricks
Sensation: big toe
5. Sensitivity to pinpricks
6. Sensitivity to touch
7. Vibration perception
8. Sensitivity to joint position
Only the right leg and foot are tested.
Scoring from 0 to 2:
0 = Normal
1 = Mild/moderate deficit
• Muscle strength: Medical Research
Council scale 3–4
• Reflex: decreased but present
• Sensation: decreased but present
2 = Severely disturbed/absent




Maximum score: 16 points
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